Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
Status:
Active, not recruiting
Trial end date:
2022-08-19
Target enrollment:
Participant gender:
Summary
After failure on docetaxel, which has been the standard first line therapy for patients with
metastatic castration-resistant prostate cancer (mCRPC), several treatment options are
currently available.
In retrospective studies, resistance has been described to two of the treatment options,
enzalutamide and abiraterone, when a splice variant of the Androgen Receptor (AR-V7) is
present on circulating tumor cells (CTCs). The investigators hypothesize that patients with
AR-V7 positive CTCs do have a meaningful response to cabazitaxel.